loading
Schlusskurs vom Vortag:
$21.32
Offen:
$21.46
24-Stunden-Volumen:
1.97M
Relative Volume:
1.00
Marktkapitalisierung:
$3.60B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
118.56
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
-9.58%
1M Leistung:
-17.89%
6M Leistung:
+28.48%
1J Leistung:
+38.75%
1-Tages-Spanne:
Value
$20.87
$21.48
1-Wochen-Bereich:
Value
$20.02
$21.86
52-Wochen-Spanne:
Value
$13.40
$26.65

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
Firmenname
Acadia Pharmaceuticals Inc
Name
Telefon
858-558-2871
Name
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Name
Mitarbeiter
654
Name
Twitter
@acadiapharma
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
ACAD's Discussions on Twitter

Vergleichen Sie ACAD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
21.34 3.60B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
391.64 101.35B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.00 58.66B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
562.27 59.43B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
737.56 44.01B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
340.70 36.56B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-21 Hochstufung Deutsche Bank Hold → Buy
2025-02-11 Eingeleitet Deutsche Bank Hold
2025-01-03 Herabstufung Guggenheim Buy → Neutral
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-08-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-06-27 Eingeleitet BMO Capital Markets Outperform
2024-03-12 Herabstufung Mizuho Buy → Neutral
2024-03-12 Bestätigt Needham Buy
2024-01-30 Eingeleitet Robert W. Baird Outperform
2024-01-24 Hochstufung Needham Hold → Buy
2023-12-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-12-14 Herabstufung Deutsche Bank Buy → Hold
2023-12-13 Eingeleitet Citigroup Buy
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-11-06 Hochstufung Mizuho Neutral → Buy
2023-10-17 Eingeleitet UBS Buy
2023-10-10 Hochstufung JP Morgan Neutral → Overweight
2023-01-03 Hochstufung Guggenheim Neutral → Buy
2022-11-04 Herabstufung Goldman Neutral → Sell
2022-11-01 Eingeleitet Loop Capital Hold
2022-08-08 Herabstufung Citigroup Buy → Neutral
2022-08-05 Herabstufung Citigroup Buy → Neutral
2022-06-21 Herabstufung Jefferies Buy → Underperform
2022-06-16 Hochstufung Jefferies Hold → Buy
2022-03-16 Hochstufung Canaccord Genuity Hold → Buy
2022-02-09 Hochstufung H.C. Wainwright Neutral → Buy
2022-01-05 Hochstufung Citigroup Neutral → Buy
2021-12-21 Herabstufung Guggenheim Buy → Neutral
2021-11-01 Hochstufung Guggenheim Neutral → Buy
2021-10-14 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-09-23 Fortgesetzt Needham Hold
2021-06-10 Eingeleitet Berenberg Hold
2021-04-07 Herabstufung H.C. Wainwright Buy → Neutral
2021-04-06 Herabstufung Canaccord Genuity Buy → Hold
2021-04-06 Herabstufung Goldman Buy → Neutral
2021-04-06 Herabstufung Jefferies Buy → Hold
2021-04-06 Herabstufung Mizuho Buy → Neutral
2021-04-05 Herabstufung Raymond James Outperform → Mkt Perform
2021-03-10 Herabstufung BofA Securities Buy → Neutral
2021-03-09 Herabstufung Citigroup Buy → Neutral
2021-03-09 Herabstufung Guggenheim Buy → Neutral
2021-03-09 Bestätigt H.C. Wainwright Buy
2021-03-09 Herabstufung Raymond James Strong Buy → Outperform
2021-03-09 Herabstufung Stifel Buy → Hold
2020-12-16 Eingeleitet Mizuho Buy
2020-11-16 Hochstufung Raymond James Outperform → Strong Buy
2020-08-25 Eingeleitet Raymond James Outperform
2020-08-20 Eingeleitet Morgan Stanley Overweight
2020-07-07 Hochstufung Stifel Hold → Buy
2020-04-16 Eingeleitet Jefferies Buy
2020-03-31 Hochstufung Goldman Neutral → Buy
2020-03-06 Eingeleitet Citigroup Buy
2019-12-16 Eingeleitet Guggenheim Buy
2019-10-24 Eingeleitet Oppenheimer Perform
2019-10-01 Eingeleitet RBC Capital Mkts Outperform
2019-09-13 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-09-10 Hochstufung Canaccord Genuity Hold → Buy
2019-07-23 Bestätigt Needham Buy
2018-12-10 Eingeleitet Canaccord Genuity Hold
2018-09-21 Hochstufung Piper Jaffray Neutral → Overweight
2018-08-09 Bestätigt Stifel Hold
2018-08-07 Eingeleitet Stifel Hold
2018-08-06 Herabstufung Piper Jaffray Overweight → Neutral
2017-10-06 Fortgesetzt Goldman Neutral
Alle ansehen

Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten

pulisher
Sep 30, 2025

Acadia’s Prader-Willi miss gives Tonix a chance at the market - BioCentury

Sep 30, 2025
pulisher
Sep 30, 2025

Why ACADIA Pharmaceuticals Inc. stock could be next big winner2025 Dividend Review & Entry Point Confirmation Signals - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

News impact scoring models applied to ACADIA Pharmaceuticals Inc.Price Action & Reliable Volume Spike Trade Alerts - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

JP Morgan Updates ACADIA Pharmaceuticals (ACAD) Analyst Rating | - GuruFocus

Sep 29, 2025
pulisher
Sep 29, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $33.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Will ACADIA Pharmaceuticals Inc. rebound enough to break evenMarket Sentiment Report & Fast Entry High Yield Stock Tips - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Using R and stats models for ACADIA Pharmaceuticals Inc. forecastingWeekly Investment Report & Verified Swing Trading Watchlist - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

Real time social sentiment graph for ACADIA Pharmaceuticals Inc.Insider Selling & Real-Time Stock Movement Alerts - newser.com

Sep 28, 2025
pulisher
Sep 28, 2025

Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps - MSN

Sep 28, 2025
pulisher
Sep 28, 2025

What analysts say about ACADIA Pharmaceuticals Inc stockMomentum Stock Picks & Budget Friendly Growth - earlytimes.in

Sep 28, 2025
pulisher
Sep 27, 2025

What drives ACADIA Pharmaceuticals Inc stock priceAnalyst Downgrades & Market Crushing Stock Picks - Early Times

Sep 27, 2025
pulisher
Sep 27, 2025

What machine learning models say about ACADIA Pharmaceuticals Inc.Index Update & Long-Term Growth Plans - newser.com

Sep 27, 2025
pulisher
Sep 26, 2025

Detecting price anomalies in ACADIA Pharmaceuticals Inc. with AIInsider Selling & Stepwise Trade Execution Plans - newser.com

Sep 26, 2025
pulisher
Sep 26, 2025

Using flow based indicators on ACADIA Pharmaceuticals Inc.2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com

Sep 26, 2025
pulisher
Sep 26, 2025

Acadia drops development of carbetocin in PWS - The Pharma Letter

Sep 26, 2025
pulisher
Sep 25, 2025

Acadia to stop development of rare disease therapy after trial failure - ET Pharma

Sep 25, 2025
pulisher
Sep 25, 2025

ACADIA Pharmaceuticals Hits Day Low of $20.03 Amid Price Pressure - Markets Mojo

Sep 25, 2025
pulisher
Sep 25, 2025

Acadia Pharmaceuticals stock price target maintained by BMO after trial miss - Investing.com Canada

Sep 25, 2025
pulisher
Sep 25, 2025

ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure - sharewise.com

Sep 25, 2025
pulisher
Sep 25, 2025

Acadia Pharmaceuticals Hit by Trial Failure for Prader-Willi Syndrome, Deutsche Bank Says - MarketScreener

Sep 25, 2025
pulisher
Sep 25, 2025

A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $35 - 富途牛牛

Sep 25, 2025
pulisher
Sep 25, 2025

Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $29 From $35, Maintains Buy Rating - MarketScreener

Sep 25, 2025
pulisher
Sep 25, 2025

Acadia, Harmony record late-stage rare disease failures - pharmaphorum

Sep 25, 2025
pulisher
Sep 25, 2025

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint - BioSpace

Sep 25, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals stock price target lowered to $35 at TD Cowen - Investing.com

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Gives Up In PWS After Another ACP-101 Phase III Miss - insights.citeline.com

Sep 24, 2025
pulisher
Sep 24, 2025

Oppenheimer cuts Acadia Pharmaceuticals stock price target after failed study By Investing.com - Investing.com UK

Sep 24, 2025
pulisher
Sep 24, 2025

Biotech Stocks Diverge As Genetic Disease Drug Fails - Investor's Business Daily

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia grounds Prader-Willi candidate after trial failure, leaving the market to Soleno - Fierce Pharma

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals: Reeling After PWS FailureDowngrading To Hold (NASDAQ:ACAD) - Seeking Alpha

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals stock drops after ACP-101 misses endpoint By Investing.com - Investing.com Canada

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges - MSN

Sep 24, 2025
pulisher
Sep 24, 2025

BMO Capital reiterates Acadia Pharmaceuticals stock rating despite trial failure - Investing.com Canada

Sep 24, 2025
pulisher
Sep 24, 2025

Oversold Conditions For Acadia Pharmaceuticals (ACAD) - Nasdaq

Sep 24, 2025
pulisher
Sep 24, 2025

ACAD: Latest Developments and Market Insights - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals (ACAD) Faces Setback After Phase 3 Trial Results - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

ACADIA Pharmaceuticals (ACAD): Needham Lowers Price Target, Maintains Buy Rating | ACAD Stock News - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Down Following Analyst Downgrade - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia to scrap Prader-Willi drug after study setback - BioPharma Dive

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals stock drops after ACP-101 misses endpoint - Investing.com

Sep 24, 2025
pulisher
Sep 24, 2025

Needham & Company LLC Has Lowered Expectations for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals stock unchanged as BofA maintains Neutral rating By Investing.com - Investing.com UK

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia, with a failed phase III, drops Prader-Willi candidate - BioWorld MedTech

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia’s phase 3 trial for Prader-Willi syndrome drug fails to meet goals - Investing.com Australia

Sep 24, 2025
pulisher
Sep 24, 2025

Traders Buy Large Volume of ACADIA Pharmaceuticals Call Options (NASDAQ:ACAD) - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals (ACAD) Experiences Significant Drop in St - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Optimistic Outlook for ACADIA Pharmaceuticals Despite Recent Setback: Buy Rating and $32 Price Target - TipRanks

Sep 24, 2025
pulisher
Sep 24, 2025

Leerink on Acadia (ACAD): 'Despite the news, we still like the stock' - StreetInsider

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Scraps Prader-Willi Drug After Late-Stage Failure - BioSpace

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - Benzinga

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals (ACAD) Shares Dip After Trial Disappointm - GuruFocus

Sep 24, 2025

Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.66
price down icon 2.36%
$84.81
price up icon 1.10%
$30.67
price up icon 4.57%
$98.62
price up icon 0.53%
$144.01
price up icon 1.67%
biotechnology ONC
$340.70
price up icon 2.36%
Kapitalisierung:     |  Volumen (24h):